A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）

Inclusion Criteria:

1. Male and female participants ≥ 18 years of age;

2. Diagnosis of PNH based on flow cytometry with clone size > 10% by granulocytes;

3. Have not received complement inhibitor treatment;

4. Blood lactate dehydrogenase(LDH) values > 1.5 ×upper limit of the normal range (ULN) ;

5. Hemoglobin level < 100 g/L during the screening period.

Exclusion Criteria:

1. Hereditary or acquired complement deficiency;

2. Active primary or secondary immunodeficiency;

3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organtransplants;

4. History of recurrent invasive infections caused by encapsulated organisms( e.g.meningococcus or pneumococcus) or Mycobacterium tuberculosis;

5. Patients with laboratory evidence of bone marrow failure (reticulocytes < 100x10^9/L, or platelets < 30x10^9/L or neutrophils < 0.5x10^9/L) ;

6. Active systemic infection within 2 weeks prior to study drug administration;

7. History of serious comorbidities that have been determined to be unsuitable forparticipation in the study.

8. Pregnant or Lactating women.